EuroBiotech Report—MorphoSys-Incyte, Adaptimmune deal, Galapagos, BioNTech and Ipsen

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with MorphoSys, which unveiled a much-anticipated deal for its anti-CD19 antibody tafasitamab. Incyte took the other side of the deal, paying $750 million upfront for near-global rights. Elsewhere, Adaptimmune climbed out of a slump on the back of clinical data and a cell therapy deal with Astellas. Galapagos returned to Fibrocor to pick up options on four more fibrosis candidates. BioNTech struck a deal to buy Neon Therapeutics. Ipsen appointed Steven Hildemann as its chief medical officer. And more. — Nick Taylor
 
1. Incyte pays $750M upfront for rights to MorphoSys cancer drug

Incyte is set to pay MorphoSys $750 million upfront for rights to anti-CD19 antibody tafasitamab. The licensing deal, which features a $150 million equity investment and up to $1.1 billion in milestones, gives Incyte a big stake in a near-approval asset that achieved CAR-T-like efficacy in lymphoma patients.
 
2. Astellas teams with Adaptimmune to create CAR-T, TCR therapies

Astellas has teamed up with Adaptimmune to develop allogeneic chimeric antigen receptor T-cell and T-cell receptor therapies. The agreement sees Astellas pay $50 million (€45 million) upfront and commit to many times as much in milestones to work with Adaptimmune to identify targets and develop cell therapies against them.
 
3. Galapagos bags option on 4 more Fibrocor programs

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

Galapagos has struck another deal to expand its fibrosis pipeline, picking up an option to license four Fibrocor programs. The deal comes one year after Galapagos landed global rights to an early-stage idiopathic pulmonary fibrosis treatment in development at Fibrocor.
 
4. After IPO, BioNTech nabs cell therapy startup Neon Therapeutics

Germany’s BioNTech, which has gotten off some monster raises, is paying just $67 million in an all-stock deal to snap up Neon Therapeutics and its early-stage T-cell work.
 
5. Ex-Merck Serono CMO takes up medical role at struggling Ipsen in its evolving C-suite

Steven Hildemann, M.D., Ph.D., is set to join Parisian biotech Ipsen as its new executive vice president and chief medical officer as the company looks to overturn a clinical hold and steady the ship under a new CEO.
 
And more articles of note>>

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.